Agenzia delle Entrate, Risoluzine n. 88 del 19 ottobre 2015
Continue reading
Daily Archives: 20/10/2015
Oggi in Consiglio di Stato 20 ottobre 2015
numero sentenza, oggetto, in fondo file unico con sentenze
4794 regolamentazione degli orari delle sale da gioco
4795 affidamento del servizio di progettazione, implementazione, realizzazione e fornitura dell’architettura software
4796 affidamento del servizio di verifica non distruttiva di corrosione pali
Un whistleblower riceve 31,83 milioni di dollari, come parte dei 256 milioni pagati da Millenium Health al Governo USA
Millenium Healt ha “patteggiato” il pagamento di 256 milioni di dollari per porre fine al contenzioso per aver fatturato al servizio sanitario test genetici e delle urine non necessari, e per aver fornito regalie ai medici che accettavano di indirizzare i costosi test di laboratorio alla Millenium; questo l’annuncio del Dipartimento della Giustizia statunitense.
Il whistleblower, cioè colui che ha segnalato l’irregolarità da cui è partita l’inchiesta, riceverà 30,35 milioni per la vicenda dei test delle urine, e 1,48 milioni per la vicenda dei test genetici.
Millenium è una delle più grandi catene di laboratori negli USA.
Millenium ha accettato di pagare, poichè ha sistematicamente fatturato al servizio sanitario test delle urine non necessari da gennaio 2008 fino a maggio 2015. Gli USA li hanno accusati di fornire alcuni test gratis ai medici, in cambio del vincolo scritto di indirizzare i campioni biologici ai laboratori della Millenium.
Questo viola la Stark Law, che vieta di corrispondere qualsivoglia utilità ai medici prescrittori.
A whistleblower will receive $31,83 million, share of $256 million paid from Millenium Health
Millennium Health, formerly Millennium Laboratories, has agreed to pay $256 million to resolve alleged violations of the False Claims Act for billing Medicare, Medicaid and other federal health care programs for medically unnecessary urine drug and genetic testing and for providing free items to physicians who agreed to refer expensive laboratory testing business to Millennium, the Justice Department announced today.
The whistleblowers will receive $30.35 million from the False Claims Act recovery for the urine drug testing claims and $1.48 million from the False Claims Act recovery for the genetic testing claims.
Millennium, headquartered in San Diego, is one of the largest urine drug testing laboratories in the United States and conducts business nationwide.
As part of today’s announced settlements, Millennium has agreed to pay $227 million to resolve False Claims Act allegations, detailed in a complaint filed by the United States, that Millennium systematically billed federal health care programs for excessive and unnecessary urine drug testing from Jan. 1, 2008, through May 20, 2015. The United States alleged that Millennium caused physicians to order excessive numbers of urine drug tests, in part through the promotion of “custom profiles,” which, instead of being tailored to individual patients, were in effect standing orders that caused physicians to order large number of tests without an individualized assessment of each patient’s needs. This practice violated federal healthcare program rules limiting payment to services that are reasonable and medically necessary for the treatment and diagnosis of an individual patient’s illness or injury. The United States also alleged that Millennium’s provision of free point of care urine drug test cups to physicians—expressly conditioned on the physicians’ agreement to return the urine specimens to Millennium for hundreds of dollars’ worth of additional testing—violated the Stark Law and the Anti-Kickback Statute. The Stark Law and the Anti-Kickback Statute generally prohibit laboratories from giving physicians anything of value in exchange for referrals of tests.
Millennium has also agreed to pay $10 million to resolve False Claims Act allegations that it submitted false claims to federal health care programs from Jan. 1, 2012, through May 20, 2015, for genetic testing that was performed routinely and without an individualized assessment of need.
The False Claims Act allegations resolved were originally brought in lawsuits filed by whistleblowers under the qui tamprovisions of the False Claims Act, which allow private parties to bring suit on behalf of the government and to share in any recovery. Under the act, the United States can elect to intervene in an action filed by a whistleblower, as it did, in part, with respect to several of the qui tamactions regarding urine drug testing allegations.